Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
33results about How to "Meet the pharmaceutical requirements for production, transportation and storage" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
I-type crystal of dibenzenesulfonate of inhibitor of protein tyrosine kinase
InactiveCN104788435AImprove stabilityThe production process is stable, repeatable and controllableOrganic active ingredientsOrganic chemistry methodsProtein-Tyrosine KinasesX-ray
The invention relates to a I-type crystal of dibenzenesulfonate of an inhibitor of protein tyrosine kinase. Specifically, the invention relates to a I-type crystal of lapatinib dibenzenesulfonate. The crystal, radiated by Cu-K<alpha>, has the following characteristic peaks, represented by a 2theta angle and an inter-planar distance in an X-ray powder diffraction pattern: 6.21(14.23), 10.02(8.82), 12.11(7.30), 13.26(6.67), 13.55(6.53), 13.79(6.42), 14.88(5.95), 6.70(5.31), 17.59(5.04), 18.26(4.86), 18.93(4.68), 19.61(4.52), 20.71(4.29), 21.06(4.21), 22.19(4.00), 23.60(3.77), 24.20(3.68), 24.58(3.62), 25.10(3.55), 25.85(3.44), 26.75(3.33), 30.83(2.90), and 32.89(2.72). According to the invention, the I-type crystal of lapatinib dibenzenesulfonate has better stability, and can be preferably used for clinic treatment.
Owner:JIANGSU HENGRUI MEDICINE CO LTD
Crystal form of pyrazoloheteroaryl derivative and preparation method of crystal form of pyrazoloheteroaryl derivative
ActiveCN110526918AMeet the pharmaceutical requirements for production, transportation and storageStable production processOrganic active ingredientsOrganic chemistry methodsClinical treatmentCrystal
The invention relates to a crystal form of a pyrazoloheteroaryl derivative and a preparation method thereof, in particular to a crystal form A, a crystal form B, a crystal form C, a crystal form D, acrystal form E, a crystal form F, a crystal form G, and a crystal form H of 6-butyloxy-1-(4-(pyrrolidin-1-group-methyl)-benzyl)-IH-pyrazolo[3,4-d]pyrimidin-4-amine and a preparation method thereof. The crystal form of the compound of formula (I) is good in crystal form stability and can be better used in clinical treatment.
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1
Crystallization form of BTK inhibitor, and preparation method thereof
ActiveCN106939002AImprove stabilityMeet the pharmaceutical requirements for production, transportation and storageOrganic chemistryPyridazineSolvent
The invention relates to a crystallization form of a BTK inhibitor, and a preparation method thereof, and concretely relates to a type I crystal of (R)-1-(3-(4-amino-3-(4-(2,6-difluorophenoxy)phenyl)-7-hydroxy-1H-pyrrolo[2,3-d]pyridazine-1-yl)piperidine-1-yl)propyl-2-ene-1-one (compound of formula (I)), and a preparation method thereof. The type I crystal of the compound (I) obtained in the invention has the advantages of good chemical stability and crystal form stability, and a crystallization solvent used in the invention has low toxicity and low residual, so the type I crystal of the compound (I) can be well used in clinic treatment.
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1
S-Manidipine hydrochloride crystal form I and preparation method thereof
ActiveCN105924382AGood crystal stabilityStable production processOrganic active ingredientsOrganic chemistry methodsManidipine hydrochlorideX-ray
The invention relates to an S-Manidipine hydrochloride crystal form I and a preparation method thereof. The preparation method includes: dissolving S-Manidipine free alkali into alcohols or alcohol / water, salifying with HCL, and crystallizing to obtain S-Manidipine hydrochloride crystal which is determined as the crystal form I according to X-ray powder diffraction detection. Products of the S-Manidipine hydrochloride crystal form I have excellent temperature and humidity stability, meet quality requirements on residual solvent and moisture and are suitable for preparation process and long-term storage. Pharmaceutical compositions with compounds of the crystal form I serving as active ingredients can be used for treating diseases such as hypertension and the like.
Owner:YANGTZE RIVER PHARMA GRP BEIJING HAIYAN PHARMA
Crystal form of cyclin dependent protein kinase inhibitor and preparation method thereof
ActiveCN106065016AImprove stabilityMeet the pharmaceutical requirements for production, transportation and storageOrganic active ingredientsOrganic chemistry methodsCyclin-Dependent Kinase Inhibitor GeneX-ray
The invention relates to a crystal form of a cyclin dependent protein kinase inhibitor and a preparation method thereof. Specifically, the invention relates to a type I crystal of a cyclin dependent protein kinase (CDK4&6) inhibitor and a preparation method thereof. Specifically, the invention relates to a type I crystal of 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperidine-4-yl)pyridine-2-yl)amino)pyridine[2, 3-d]pyrimidine-7(8H)-one (formula (I) compound) and a preparation method thereof, wherein the crystal has an X-ray powder diffraction spectrum shown as Figure 1. The type I crystal of the formula (I) compound obtained by the invention has good chemical stability and crystal form stability, and the used crystal solvent has low toxicity and low residue, thus being better applicable to clinical treatment. (formula (I)).
Owner:JIANGSU HENGRUI MEDICINE CO LTD
I type crystal of L-alanine-(14-rubescensin A)-ester trifluoroacetate, and preparation method thereof
InactiveCN105131009AGood crystal stabilityStable production processOrganic active ingredientsOrganic chemistrySolventRubescensin S
The present invention relates to an I-type crystal of L-alanine-(14-oridonin) ester trifluoroacetate and a preparation method therefor.The preparation method comprises crystallizing a L-alanine-(14-oridonin) ester trifluoroacetate solid in any crystal form or amorphous form in a single organic solvent or a mixed organic solvent thereof to obtain the I-type crystal of the L-alanine-(14-oridonin) ester trifluoroacetate.The I-type crystal of the L-alanine-(14-oridonin) ester trifluoroacetate obtained in the present invention has a good crystal form stability and chemical stability, and uses a crystallization solvent which has a low toxicity and low residue, and can be better used in clinical treatments.
Owner:JIANGSU HENGRUI MEDICINE CO LTD
Crystal form of dimaleate of tyrosine kinase inhibitor and preparation method thereof
InactiveCN109206410AImprove solubilityHigh purityOrganic active ingredientsOrganic chemistry methodsTyrosine-kinase inhibitorChemical stability
The invention relates to a crystal form of dimaleate of a tyrosine kinase inhibitor and a preparation method thereof. Specifically, the invention relates to an II crystal form of dimaleate of an epidermal growth factor receptor (EGFR) inhibitor and a preparation method thereof. The II crystal form has good chemical stability and crystal form stability, and can be better used in clinical treatment.
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1
Crystal form of extrarenal medulla secretory potassium channel inhibitor and preparation method thereof
ActiveCN109879863BImprove solubilityHigh purityOrganic active ingredientsCardiovascular disorderMedicinal chemistryChemical stability
The invention relates to a crystal form of a renal outer medullary potassium channel inhibitor and a preparation method of the crystal form. Specifically, the invention relates to an IV crystal form of an L-tartrate of a renal outer medullary potassium channel (ROMK) inhibitor and a preparation method of the IV crystal form. The IV crystal form has good chemical stability and crystal form stability, a used crystallization solvent is low in toxicity and residue, and the IV crystal form can be better used for clinical treatment.
Owner:JIANGSU HENGRUI MEDICINE CO LTD +2
Free alkali crystal form of phenylpropionamide derivative and preparation method of free alkali crystal form
ActiveCN109422798ACrystal form stability Good stabilityGood crystal stabilitySenses disorderAntipyreticDiseaseAgonist
The invention relates to a free alkali crystal form of phenylpropionamide derivative and a preparation method of the free alkali crystal form. The invention particularly relates to a novel crystal form of phenylpropionamide derivative free alkali, i.e. a crystal form I of a compound shown in formula (I). The invention also relates to a preparation method of the crystal form I, a medicine composition, and an application of the medicine composition in preparing medicine for preventing and / or treating relevant KOR agonist-mediated diseases. The crystal form I of the compound shown in the formula(I) has good stability and can be better used for clinic treatment. (Shown in the description).
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1
Crystal form of intestinal type-2B sodium phosphate synergistic transportprotein inhibitor and preparation method thereof
ActiveCN109422723AImprove stabilityMeet the pharmaceutical requirements for production, transportation and storageOrganic active ingredientsMetabolism disorderIntestinal typeMorpholine
The invention relates to a crystal form of an intestinal type-2B sodium phosphate synergistic transportprotein inhibitor and a preparation method thereof, in particular to a crystal form II of N<1>-methyl-N<1>-(2-morpholine ethyl)-N<3>-(3-(4-phenylethyl phenylcarbamyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-yl)isophthalamide sulfate (a compound shown in formula (I)) and a preparation method. The crystal form II of the compound in formula (I) obtained in the invention has good chemical stability and crystal form stability and can be well applied to the clinical treatment. (Shown in the description).
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1
I-type crystallization and preparation method of l-alanine-(14-oridonin A) ester trifluoroacetate
ActiveCN105636964BStable production processGood crystal stabilityOrganic active ingredientsOrganic chemistryOrganic solventTrifluoroacetic acid
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1
A crystalline form of a cyclin-dependent protein kinase inhibitor and a preparation method thereof
ActiveCN106065016BImprove stabilityMeet the pharmaceutical requirements for production, transportation and storageOrganic active ingredientsOrganic chemistry methodsPTK InhibitorsCyclin
The invention relates to a crystal form of a cyclin dependent protein kinase inhibitor and a preparation method thereof. Specifically, the invention relates to a type I crystal of a cyclin dependent protein kinase (CDK4&6) inhibitor and a preparation method thereof. Specifically, the invention relates to a type I crystal of 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperidine-4-yl)pyridine-2-yl)amino)pyridine[2, 3-d]pyrimidine-7(8H)-one (formula (I) compound) and a preparation method thereof, wherein the crystal has an X-ray powder diffraction spectrum shown as Figure 1. The type I crystal of the formula (I) compound obtained by the invention has good chemical stability and crystal form stability, and the used crystal solvent has low toxicity and low residue, thus being better applicable to clinical treatment. (formula (I)).
Owner:JIANGSU HENGRUI MEDICINE CO LTD
Iptakalim hydrochloride B crystal form and preparation method thereof
ActiveCN112174834AHigh crystal purityHigh purityOrganic active ingredientsAmino compound purification/separationBioavailabilityMedicinal chemistry
The invention relates to an iptakalim hydrochloride B crystal form and a preparation method thereof, and the obtained iptakalim hydrochloride B crystal form has good crystal form stability and chemical stability, has good bioavailability, and can be better used for clinical treatment.
Owner:江苏恩华赛德药业有限责任公司 +1
Novel crystal form of midazolam hydrochloride and preparation method thereof
ActiveCN111320632BGood chemical stabilityHigh purityOrganic active ingredientsNervous disorderMidazolam hclMedicine
The invention relates to a crystal form A and crystal B of midazolam hydrochloride and a preparation method thereof. The crystal form A and crystal B of midazolam hydrochloride obtained in the present invention have good crystal form stability and chemical stability Sex, can be better used in clinical treatment,
Owner:NHWA PHARMA CORPORATION
Crystal form of renal outer medullary potassium channel inhibitor and preparation method of crystal form
ActiveCN109879863AImprove solubilityHigh purityOrganic active ingredientsCardiovascular disorderRENAL OUTER-MEDULLARY POTASSIUM CHANNELPotassium
The invention relates to a crystal form of a renal outer medullary potassium channel inhibitor and a preparation method of the crystal form. Specifically, the invention relates to an IV crystal form of an L-tartrate of a renal outer medullary potassium channel (ROMK) inhibitor and a preparation method of the IV crystal form. The IV crystal form has good chemical stability and crystal form stability, a used crystallization solvent is low in toxicity and residue, and the IV crystal form can be better used for clinical treatment.
Owner:JIANGSU HENGRUI MEDICINE CO LTD +2
Itakaline hydrochloride A crystal form and preparation method thereof
ActiveCN112174833BHigh crystal purityHigh purityOrganic active ingredientsAmino compound purification/separationCombinatorial chemistryBioavailability
The present invention relates to a crystal form A of ertacarline hydrochloride and a preparation method thereof. The crystal form A of ertacarline hydrochloride obtained in the present invention has good crystal form stability and chemical stability, and has good bioavailability It can be better used in clinical treatment.
Owner:江苏恩华赛德药业有限责任公司 +1
A kind of crystalline form of opioid receptor (mor) agonist and preparation method
ActiveCN112638907BHigh melting pointImprove solubilityOrganic active ingredientsOrganic chemistryEthoxidineEthyl group
The present disclosure provides a crystalline form of an opioid receptor (MOR) agonist and a preparation method thereof. Specifically, the present disclosure provides (1S,4S)-4-ethoxy-N-(2-((R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decane-9- Base) ethyl)-1,2,3,4-tetrahydronaphthalene-1-amine fumarate III crystal form and preparation method thereof. The III crystal form of the compound of formula (I) in the present disclosure has good crystal stability and can be better used in clinical treatment.
Owner:JIANGSU HENGRUI MEDICINE CO LTD
Crystal form of intestinal 2b type sodium phosphate cotransporter inhibitor and preparation method thereof
ActiveCN109422723BImprove stabilityMeet the pharmaceutical requirements for production, transportation and storageOrganic active ingredientsMetabolism disorderIntestinal typeSodium phosphates
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1
A kind of crystalline form of propionamide derivatives and preparation method thereof
ActiveCN113195484BForm A has high purityGood crystal stabilityOrganic active ingredientsNervous disorderCompound aPerylene derivatives
The present invention relates to a crystal form A of propionamide derivatives and a preparation method thereof. The crystal form A of the compound of formula (1) obtained in the present invention has good crystal form stability and chemical stability, and can be used better in clinical treatment.
Owner:NHWA PHARMA CORPORATION
Itakaline hydrochloride B crystal form and preparation method thereof
ActiveCN112174834BHigh crystal purityHigh purityOrganic active ingredientsAmino compound purification/separationBioavailabilityMedicinal chemistry
The present invention relates to a B crystal form of ertacarline hydrochloride and a preparation method thereof. The B crystal form of ertacarline hydrochloride obtained in the present invention has good crystal form stability and chemical stability, and has good bioavailability , can be better used in clinical treatment.
Owner:江苏恩华赛德药业有限责任公司 +1
Crystal form of free base of imidazoisoindole derivatives and preparation method thereof
ActiveCN109384791BLittle change in purityGood chemical stabilityOrganic active ingredientsSenses disorderPhenyl groupPyrrole
The invention relates to a crystal form of a free alkali of an imidazoisoindole derivative and a preparation method thereof. Specifically, the invention relates to the crystal form II of a compound asshown in a formula (I) which is described in the specification, and the chemical name of the crystal form II is (S)-2-(4-(4-(4-(6-fluoro-5H-imidazo[5,1-a]isoindol-5-yl)piperidin-1-yl)phenyl)-1H-pyrazol-1-yl)ethanol. The invention further relates to the preparation method of the crystal form II, the application of the crystal form II to a pharmaceutical composition, and the application of the crystal form II and the composition to the treatment of diseases having pathological features of an IDO-mediated (indoleamine-pyrrole-2,3-dioxygenase-mediated) tryptophan metabolism approach. The preparedcrystal form II of the compound as shown in the formula (I) has good stability and can be better used for clinical treatment.
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1
Pharmaceutically acceptable salt, crystal form and preparation method of pyrazoloheteroaryl derivatives
ActiveCN110526917BGood chemical stabilityLittle change in purityOrganic active ingredientsOrganic chemistry methodsCrystallographyPerylene derivatives
The invention relates to a pharmaceutically acceptable salt, crystal form and preparation method of pyrazolo heteroaryl derivatives. The new pharmaceutically acceptable salt and the new crystal form of the present invention have good stability and can be better used in clinical treatment.
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1
A crystal form of a spirocyclic dihydroisoquinoline carboxamide derivative and a preparation method thereof
ActiveCN111217748BHigh crystal purityGood crystal stabilityOrganic active ingredientsAntipyreticIsoquinolineQuinoline
The invention relates to a crystal form of a spirocyclic dihydroisoquinoline carboxamide derivative and a preparation method thereof. Specifically, the present invention relates to the crystal form A of the compound represented by formula (I), which has good stability and can be better used in clinical treatment.
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1
Medicinal salt for pyrazolo-heteroaryl derivative and crystal form and preparation method of medicinal salt
ActiveCN110526917AGood chemical stabilityLittle change in purityOrganic active ingredientsOrganic chemistry methodsMedicinePyrazole
The invention relates to a medicinal salt for a pyrazolo-heteroaryl derivative and a crystal form and a preparation method of the medicinal salt. The new medicinal salt and the new crystal form have the good stability, and can be better used in clinical treatment.
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1
A kind of salt of benzopiperidine derivatives, its crystal form and salt, the preparation method of its crystal form
ActiveCN110536888BImprove solubilityCrystallizes wellOrganic active ingredientsOrganic chemistryQuinolinePerylene derivatives
Disclosed are a salt of a benzopiperidine derivative, a crystal form thereof, a preparation method of the salt and the crystal form thereof. Specifically, (E)-3-(4-((1R,3R)-2-(4-cyclopropylphenyl)-6-(1-ethyl-1H-pyrazole-4-yl) is disclosed -3-methyl-1,2,3,4-tetrahydroisoquinoline-1-yl) phenyl) acrylic acid L-lysine salt, its I crystal form and preparation method thereof. The compound of formula (I) and its crystal form I have good stability, simple process and easy operation, and can be better used for clinical treatment.
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1
Crystal form and preparation method of a pyrazoloheteroaryl derivative
ActiveCN110526918BMeet the pharmaceutical requirements for production, transportation and storageStable production processOrganic active ingredientsOrganic chemistry methodsArylMeth-
The invention relates to a crystal form and a preparation method of pyrazolo heteroaryl derivatives. In particular, the present invention relates to A of 6-butoxy-1-(4-(pyrrolidin-1-ylmethyl)benzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Crystal form, B crystal form, C crystal form, D crystal form, E crystal form, F crystal form, G crystal form, H crystal form and preparation methods thereof. The crystal form of the compound of formula (I) of the present invention has good crystal form stability, and can be better used in clinical treatment,
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1
Free base crystal form of phenylpropanamide derivatives and preparation method thereof
ActiveCN109422798BCrystal form stability Good stabilityGood crystal stabilitySenses disorderMetabolism disorderPharmaceutical drugCombinatorial chemistry
The invention relates to a free base crystal form of phenylpropanamide derivatives and a preparation method thereof. Specifically, the present invention relates to a new crystal form of the free base of phenylpropanamide derivatives, that is, crystal form I of the compound represented by formula (I). The present invention also relates to the preparation method of the I crystal form, the pharmaceutical composition and its use in the preparation of medicines for preventing and / or treating related diseases mediated by KOR agonists. The crystal form I of the compound of formula (I) obtained in the present invention has good stability and can be better used in clinical treatment.
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1
Crystal form of androgen receptor inhibitor and preparation method thereof
ActiveCN112174895AGood chemical stabilityLittle change in purityOrganic active ingredientsOrganic chemistry methodsAndrogen Receptor GeneSex hormone receptor
The invention relates to a crystal form of an androgen receptor inhibitor and a preparation method thereof. Specifically, the invention relates to a crystal form of an androgen receptor inhibitor as shown in a formula (I) and a preparation method thereof. The novel crystal form provided by the invention has good stability and can be better used for clinical treatment.
Owner:JIANGSU HENGRUI MEDICINE CO LTD
A polymorphic form of a gnrh receptor antagonist and a preparation method thereof
ActiveCN108778280BMeet the limit requirementsGood chemical stabilityOrganic active ingredientsOrganic chemistryDiseasePyridazine
The invention discloses a polymorphic form of a GnRH receptor antagonist and a preparation method thereof. Specifically, the present invention discloses 1-(4-(7-(2,6-difluorobenzyl)-3-((dimethylamino)methyl)-5-(6-methoxypyridazine-3- yl)-4,6-dicarbonyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-2-yl)phenyl)-3-methoxyurea ( Polymorphic forms A, B, C, D of formula (I) compound) and preparation method thereof, its application in pharmaceutical composition and this polymorphic form and composition have GnRH receptor antagonist in the preparation treatment and / or prevention Use in related diseases.
Owner:JIANGSU HENGRUI MEDICINE CO LTD
A crystalline form of malate salt of a tyrosine kinase inhibitor and a preparation method thereof
ActiveCN107629048BImprove stabilityMeet the pharmaceutical requirements for production, transportation and storageOrganic active ingredientsOrganic chemistryTyrosine-kinase inhibitorTyrosine
The invention relates to a crystallization form of malate of a tyrosine kinase inhibitor, and a preparation method thereof, and concretely relates to an II type crystal of L-malate of 5-(2-diethylamino-ethyl)-2-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidene-methyl)-3-methyl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one (a compound of formula (I)), and a preparation method thereof. The II type crystal of the compound (I) obtained in the invention has the advantages of good crystal form stability and chemical stability, and a crystallization solvent used in the invention has low toxicity and low residual, so the II type crystal of the compound (I) can be well used in clinic treatment.
Owner:JIANGSU HENGRUI MEDICINE CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com